Newron Pharmaceuticals to Participate in the Piper Jaffray 28th Annual Healthcare Conference in New York

MILAN–(BUSINESS WIRE)– Newron
Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical
company focused on the development of novel therapies for patients with
diseases of the central nervous system (CNS) and pain, today
announced that Stefan Weber, CEO, will participate in a panel discussion
“Under-discovered Neuro-Innovators” at the Piper Jaffray 28^th
Annual Healthcare Conference in New York, NY on Tuesday, November 29,
2016 at 10:00 a.m. ET.

About Newron Pharmaceuticals

Newron (SIX: NWRN) is a biopharmaceutical company focused on the
development of novel therapies for patients with diseases of the central
nervous system (CNS) and pain. The Company is headquartered in Bresso
near Milan, Italy. Xadago® (Safinamide) has received
marketing authorization for the treatment of Parkinson’s disease in the
European Union and Switzerland and is commercialized
by Newron’s Partner Zambon. US WorldMeds holds the commercialization
rights in the US. Meiji Seika has the rights to develop and
commercialize the compound in Japan and other key Asian territories. In
addition to Xadago® for Parkinson’s disease, Newron has a strong
pipeline of promising treatments for rare disease patients at various
stages of clinical development, including sarizotan for patients with
Rett syndrome and ralfinamide for patients with specific rare pain
indications. Newron is also developing NW-3509 as the potential first
add-on therapy for the treatment of patients with positive symptoms of
schizophrenia. For more information, please visit: www.newron.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161122005740/en/